SEC Tracker
Get the app

Renovaro Biosciences LNAI

Renovaro Biosciences Q1 FY24: net loss $9.2M; diluted EPS −$0.14

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Renovaro Biosciences reported for Q1 FY24, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$9.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.14No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$523KNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$2.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Renovaro Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Fibrogen FGEN public float $21M, Jun 30, 2025
  4. Lisata Therapeutics LSTA public float $24M, Jun 30, 2025
  5. Nanoviricides NNVC public float $24M, Dec 31, 2025